Zydus Lifesciences has reached a $120 million settlement with Japan-based Astellas Pharma, bringing an end to a protracted patent litigation between the two pharmaceutical companies. The agreement resolves claims related to intellectual property rights over a key drug product and removes a significant legal overhang for both parties. The settlement provides clarity on commercialization pathways while averting prolonged courtroom proceedings. Industry analysts view the resolution as strategically prudent, enabling Zydus to recalibrate its pipeline priorities and capital allocation.